In brief

After adjustment for haematocrit, the association is no longer statistically significant. The finding draws attention to blood composition when assessing NAD+ as a biomarker.

A biomarker in frailty research

Blood NAD+ concentration has been examined in relation to frailty in 529 community-dwelling Japanese older adults. Published on 16 September in GeroScience, the study identifies an initial association between lower levels and frailty. Its cross-sectional design captures measurements at one point in time rather than tracing how the relationship develops.

The influence of blood composition

The association weakens and loses statistical significance after adjustment for haematocrit, the proportion of blood volume occupied by red blood cells. Blood composition may therefore explain part of the finding. The sample in which NAD+ is measured becomes an important part of assessing its value as a biomarker.

Questions for precursor studies

The study raises a useful question for research on NAD+ precursors: how can a biological change be connected to a measurable functional benefit? Concentration alone does not resolve that step. Intervention studies with relevant clinical outcomes will be needed to assess whether, and under what conditions, a formulation can affect frailty.

Why it matters

Research on NAD+ precursors needs to connect biological measurements with relevant functional outcomes while accounting for the tissue or sample analysed.

Evidence limit

The cross-sectional design captures an association at one point in time. It establishes no causal relationship and does not assess supplement or NAD+ precursor efficacy.

Editorial note. This content is intended for industry professionals. It does not constitute medical advice, therapeutic guidance or regulatory advice. Read our editorial method.

Read the original source · GeroScience